Atyr Pharma Inc (ATYR)

$2.79 -0.17 (-5.74%)
Market Cap 268.35M
Revenue (ttm) 240,000.00
Net Income (ttm) -64.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26,675.00%
Debt to Equity Ratio 0.00
Volume 1,480,700
Avg Vol 1,397,764
Day's Range N/A - N/A
Shares Out 88.86M
Stochastic %K 13%
Beta 0.98
Analysts Strong Sell
Price Target $18.83

Latest News on ATYR

aTyr Pharma to Participate in April Investor Conferences

Apr 3, 2025, 8:00 AM EDT - 12 hours ago

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 27, 2025, 4:00 PM EDT - 7 days ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Mar 26, 2025, 8:00 AM EDT - 8 days ago

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

Mar 14, 2025, 3:10 PM EDT - 20 days ago

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:18 PM EDT - 20 days ago

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 21 days ago

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Mar 12, 2025, 4:00 PM EDT - 22 days ago

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Mar 6, 2025, 4:02 PM EST - 4 weeks ago

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Mar 4, 2025, 8:00 AM EST - 4 weeks ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Feb 24, 2025, 8:00 AM EST - 5 weeks ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Jan 29, 2025, 8:00 AM EST - 2 months ago

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

Dec 12, 2024, 4:00 PM EST - 4 months ago

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

Dec 9, 2024, 8:00 AM EST - 4 months ago

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

Nov 15, 2024, 8:00 AM EST - 4 months ago

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma: The Bull Has Finally Come Out

Oct 24, 2024, 1:00 PM EDT - 5 months ago

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Oct 14, 2024, 8:00 AM EDT - 6 months ago

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 9, 2024, 4:37 AM EDT - 7 months ago

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

aTyr Pharma to Participate in September Investor Conferences

Aug 21, 2024, 8:00 AM EDT - 8 months ago

aTyr Pharma to Participate in September Investor Conferences

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Aug 13, 2024, 4:00 PM EDT - 8 months ago

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

Jun 3, 2024, 8:00 AM EDT - 10 months ago

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

May 15, 2024, 7:00 AM EDT - 11 months ago

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

May 14, 2024, 8:00 AM EDT - 11 months ago

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

May 2, 2024, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 11:37 PM EDT - 1 year ago

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Mar 14, 2024, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Feb 21, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Jan 18, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Nov 13, 2023, 8:00 AM EST - 1 year ago

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

aTyr Pharma to Present at November Investor Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at November Investor Conferences

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

Sep 11, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Aug 9, 2023, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

Jun 20, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

May 25, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 11, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

May 9, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

Mar 20, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

Mar 10, 2023, 5:12 PM EST - 2 years ago

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Mar 9, 2023, 4:00 PM EST - 2 years ago

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

aTyr Pharma to Present at March Investor Conferences

Mar 8, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma to Present at March Investor Conferences

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Feb 8, 2023, 4:11 PM EST - 2 years ago

aTyr Pharma Announces Commencement of Public Offering of Common Stock

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Jan 19, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

Jan 18, 2023, 8:00 AM EST - 2 years ago

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 8:32 PM EST - 2 years ago

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 10, 2022, 4:00 PM EST - 2 years ago

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

aTyr Pharma to Present at Upcoming Investor Conferences

Nov 10, 2022, 8:00 AM EST - 2 years ago

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

Nov 3, 2022, 8:02 AM EDT - 2 years ago

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

aTyr Pharma to Present at the Jefferies London Healthcare Conference

Oct 25, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the Jefferies London Healthcare Conference

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

Oct 11, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets